The first clinical findings have shown that BAT-90 makes it possible to treat onlythe area where the tumour is located, while avoiding the surrounding tissues, so as to combine treatmentefficacy and patient safety
BetaGlue Technologies has enrolled the first patient in a clinical trial withBAT-90 , the company’s cancer radiotherapy platform. The first clinical findings have shown thatBAT-90 makes it possible to treat only the area where the tumour is located, while avoiding the surroundingtissues, so as to combine treatment efficacy and patient safety.
The clinical trial in liver cancer patient has been coordinated by Professor MalkhazMizandari at the New Hospitals in Tbilisi (Georgia), an international centre of excellenceaffiliated with Thomas Jefferson University in Philadelphia (USA).
BAT-90 consists of a β radiation-emitting biocompatible matrix, delivered to patientsvia a percutaneous injection : the Yttrium-90-labelled microspheres present inside thematrix are injected into the tumour and, as the carrier takes only 120 seconds to reach full polymerisation, they are retained exclusively in the injected area . This prevents the microspheres from spreading to surrounding tissues or organs , so as to release their radiation energy only to the target tumour. Inthis way, a very low radioactive dose is needed, much lower than the one used with conventionalradio-metabolic treatments, thus enhancing treatment efficacy and patient safety.
BAT-90 opens up important horizons in oncology , bringing benefits to both patients andhealthcare systems. Indeed, BAT-90 is a therapeutic nuclear medicine solution that is extremelyprecise (it only targets the tumour area), personalised (calibrated to the patient’sclinical situation), rapid (a single injection reaching full polymerisation in just a fewminutes) and safe (the radiation energy is released where needed, avoiding exposure ofsurrounding tissues and organs and thus minimizing any risk to either patients or healthcareprofessionals).
Dr. Antonino Amato, BetaGlue Technologies’ CEO/CMO , said: “The confirmation in this first patient ofthe previous findings from the pre-clinical studies with BAT-90 opens up tremendous perspectives totherapeutic nuclear medicine in oncology, which will hopefully lead to improved outcomes and better qualityof life for patients affected by several types of cancer”.
Dr. Riccardo Palmisano, BetaGlue Technologies’ Executive Chairman , commented: “The beginning of thefirst clinical trial with BAT-90 with a positive confirmation of efficacy and safety is a very meaningfulstep for patients with solid tumours, for oncologists and radiotherapists treating them, and for BetaGlueTechnologies, which today takes a major leap forward in creating value for the shareholders who believe inour project”.